# Cannabis-based medicines for chronic neuropathic pain in adults. > **Author:** Benjamin Caplan, MD (ABFM Board Certified, MA Lic. #240562, NPI: 1962722637) > **Publisher:** CED Clinic (https://cedclinic.com) > **Canonical URL:** https://cedclinic.com/cannabis-based-medicines-chronic-neuropathic-pain/ > **Published:** 2026-03-25T21:43:17-04:00 | **Last Modified / Clinically Audited:** 2026-09-28T10:39:16-04:00 > **Clinical Summary:** Explore cannabis-based medicines for chronic neuropathic pain in adults, including evidence on efficacy and safety from recent systematic reviews. --- CED Clinical Relevance  #100High Clinical Relevance  Strong evidence or policy relevance with direct clinical implications. 🔬 Evidence Watch  |  CED Clinic Neuropathic PainMeta-AnalysisEvidence-Based Medicine[Chronic Pain](https://cedclinic.com/cannabinoids-pain-management-opioid-alternative/)Cannabinoids Journal The Cochrane database of systematic reviews Study Type Meta-Analysis Population Human participants Why This Matters This Cochrane meta-analysis represents the gold standard for systematic evidence review in cannabis for neuropathic pain, a condition affecting 6-10% of the population where conventional treatments often fail. Given the substantial clinical interest in cannabis for neuropathic pain, this update provides clinicians with the most rigorous available evidence synthesis. Clinical Summary This systematic review updates the 2018 Cochrane analysis examining randomized, double-blind controlled trials of cannabis-based medicines versus placebo or active comparators for chronic neuropathic pain in adults. The review included herbal, plant-derived, and synthetic cannabinoids with treatment durations of at least two weeks. While the full results are not detailed in this abstract, Cochrane reviews typically assess both efficacy outcomes and safety profiles across included studies, providing effect size estimates and confidence intervals for clinical endpoints. Dr. Caplan’s Take “I rely heavily on Cochrane reviews for evidence-based prescribing decisions, as they represent the most methodologically rigorous approach to synthesizing clinical trial data. The 2018 version showed modest benefits with notable adverse effects, and I’m particularly interested in whether this update shows improved signal-to-noise ratios as study quality has generally improved.” Clinical Perspective 🧠 Clinicians should await the full publication to understand the specific effect sizes and safety profiles identified in this updated analysis. This review will likely inform evidence-based discussions with patients about realistic expectations for cannabis in neuropathic pain management, particularly in cases where first-line treatments have proven inadequate. 💬 Join the Conversation Have a question about how this applies to your situation? [Ask Dr. Caplan →](https://benjamincaplan.com/ask-dr-caplan) Want to discuss this topic with other patients and caregivers? [Join the forum discussion →](https://cedclinic.com/interact/discussion-forums/forum/cannabis-industry/) Have thoughts on this? Share it: [𝕏 Share on X](https://twitter.com/intent/tweet?text=Just%20read%20this%20on%20CEDclinic.com%3A%20Cannabis-based%20medicines%20for%20chronic%20neuropathic%20pain%20in%20adults.%20%40drcaplan&url=https%3A//pubmed.ncbi.nlm.nih.gov/41548880/)[in Share on LinkedIn](https://www.linkedin.com/sharing/share-offsite/?url=https%3A//pubmed.ncbi.nlm.nih.gov/41548880/)[🦥 Share on BlueSky](https://bsky.app/intent/compose?text=Just%20read%20this%3A%20Cannabis-based%20medicines%20for%20chronic%20neuropathic%20pain%20in%20adults.%20--%20via%20%40drcaplan.bsky.social%20https%3A//pubmed.ncbi.nlm.nih.gov/41548880/)[📷 Follow on Instagram](https://www.instagram.com/drbenjamincaplan/)[📝 Read more on Substack](https://substack.com/@doctorapproved)[🔔 Subscribe via RSS](https://cedclinic.com/category/cannabis-news/feed/) 📰 Source: [https://pubmed.ncbi.nlm.nih.gov/41548880/](https://pubmed.ncbi.nlm.nih.gov/41548880/) Table of Contents - [FAQ](#FAQ)[How effective are cannabis-based medicines for chronic neuropathic pain?](#How_effective_are_cannabis-based_medicines_for_chronic_neuropathic_pain) - [What types of cannabis-based medicines have been studied for neuropathic pain?](#What_types_of_cannabis-based_medicines_have_been_studied_for_neuropathic_pain) - [What are the main side effects of cannabis-based medicines for pain?](#What_are_the_main_side_effects_of_cannabis-based_medicines_for_pain) - [Who might be a candidate for cannabis-based pain treatment?](#Who_might_be_a_candidate_for_cannabis-based_pain_treatment) - [How long should cannabis-based treatment be tried before assessing effectiveness?](#How_long_should_cannabis-based_treatment_be_tried_before_assessing_effectiveness) - [Related](#Related) ## FAQ #### How effective are cannabis-based medicines for chronic neuropathic pain? Current evidence suggests that cannabis-based medicines may provide modest benefits for chronic neuropathic pain, though they help only a subset of patients. The research indicates these treatments are not superior to existing conventional therapies, but may offer an alternative option when standard treatments have failed. #### What types of cannabis-based medicines have been studied for neuropathic pain? Studies have examined herbal cannabis, plant-derived cannabinoids, and synthetic cannabinoids in randomized controlled trials. These include various formulations and delivery methods, though specific efficacy may vary between different cannabis-based products and individual patient responses. #### What are the main side effects of cannabis-based medicines for pain? Common adverse effects include dizziness, drowsiness, [cognitive impairment](https://cedclinic.com/acute-effects-partial-cb1-receptor-agonists-cognition/), and gastrointestinal symptoms. Patients should be counseled about potential impacts on driving, work performance, and daily activities, particularly during treatment initiation and dose adjustments. #### Who might be a candidate for cannabis-based pain treatment? Cannabis-based medicines may be considered for adults with chronic neuropathic pain who have not responded adequately to conventional treatments. Given that current pharmacological treatments help only a minority of neuropathic pain patients, these agents represent a potential additional therapeutic option in refractory cases. #### How long should cannabis-based treatment be tried before assessing effectiveness? Based on the study methodology requiring at least two weeks of treatment duration, a minimum trial period of 2-4 weeks is reasonable to assess initial response. However, individual response varies, and ongoing monitoring is essential to evaluate both benefits and tolerability over time. {“@context”: “https://schema.org”, “@type”: “ScholarlyArticle”, “headline”: “Cannabis-based medicines for chronic neuropathic pain in adults.”, “url”: “https://pubmed.ncbi.nlm.nih.gov/41548880/”, “about”: “cochrane database systematic reviews meta analysis”, “isPartOf”: “The Cochrane database of systematic reviews”} [https://cedclinic.com/contact/](https://cedclinic.com/contact/) Physician-Led, Whole-Person Care A doctor who takes the time to truly understand you. Personal care that starts with listening and is guided by experience and ingenuity. Health, Longevity, Wellness One-on-One Cannabis Guidance Metabolic Balance [Leave a Message](https://cedclinic.com/contact/) [Metabolic Care](https://cedclinic.com/metabolic/metabolic-how-it-works/) [Medical Consulting](https://cedclinic.com/book/) [Cannabis Care](https://cedclinic.com/book/) [https://cedclinic.com/contact/](https://cedclinic.com/contact/) RELATED READING AT CED CLINIC Continue exploring the evidence [Clinical Trial: High Doses of CBD Superior to Placebo in Treating Neuropathic Pain](https://cedclinic.com/clinical-trial-high-doses-of-cbd-superior-to-placebo-in-treating-neuropathic-pain/) Review [clinical trial results](https://cedclinic.com/cannabidiol-liver-enzyme-elevation-healthy-adults/) showing the effects of high-dose CBD on neuropathic pain relief compared to placebo. [Read the Clinical Trial](https://cedclinic.com/clinical-trial-high-doses-of-cbd-superior-to-placebo-in-treating-neuropathic-pain/) [Cannabis-based interventions might help a little with neuropathic pain – Study Summary](https://cedclinic.com/cannabis-neuropathic-pain-relief-modest-benefits/) Summary of research evaluating the modest benefits of [cannabis-based treatments](https://cedclinic.com/cannabis-medical-clinic-experience-beyond-smoking-vaping/) for neuropathic pain. [Explore the Study Summary](https://cedclinic.com/cannabis-neuropathic-pain-relief-modest-benefits/) [Endocannabinoid System Clinical Research: Pain Management Trial](https://cedclinic.com/full-spectrum-cannabis-extract-pain-trial/) Insights into [clinical research](https://cedclinic.com/cannabis-based-therapies-smoking-cessation/) on the endocannabinoid system’s role in managing [chronic pain](https://cedclinic.com/cannabinoids-pain-management-opioid-alternative/) conditions. [Learn About the Trial](https://cedclinic.com/full-spectrum-cannabis-extract-pain-trial/) ### Related --- ### Verification & Medical Governance - **Lead Clinical Author:** Benjamin Caplan, MD - **Credentials:** Board Certified in Family Medicine (ABFM), Founder & CMO CED Clinic & CED Foundation, Author of *The Doctor-Approved Cannabis Handbook* (Penguin Random House). - **Clinical Scale:** 350,000+ lifetime evaluations overseen; 81,008-patient Real-World Evidence Registry (`~/.ced_rwe_vault.db`); 125,000+ peer-reviewed study literature observatory (`http://localhost:8768/api/explorer/terminal`). - **License Verification:** Commonwealth of Massachusetts License #240562 (https://checkahealthlicense.mass.gov/). - **NPI Registry:** 1962722637 (https://npiregistry.cms.hhs.gov/provider-view/1962722637). - **Ethics & Data Privacy:** Clinical registry observations adhere strictly to HIPAA Safe Harbor de-identification (45 CFR § 164.514(b)) and criteria for secondary research exemption under 45 CFR § 46.104(d)(4).